Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for KB707 (IL-2 and IL-12) in Gorlin syndrome. The expected timing is based on the latest available company guidance and may change.
OPAL-1 study. 10/2023- First patient dosed. 5/6/25- Enrollment ongoing. 8/21/25- Paused further development and focus on the inhaled version. 11/03/25:- OPAL-1 enrollment paused; patients followed; future intratumoral KB707 development plans under evaluation. 02/17/26:- OPAL-1 patients continue in follow-up; future intratumoral KB707 plans depend on accumulating data. 05/04/26:- OPAL-1 patients remain in follow-up; intratumoral KB707 development plans await additional safety and efficacy data. 08/03/26:- OPAL-1 enrolled three Gorlin patients; interim update and development plans due H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.